Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 9037 results

  1. Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Surgical mesh for treatment of non-primary ventral hernias

    In development Reference number: GID-HTG10165 Expected publication date: TBC

    HealthTech guidance
    In development

  3. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Budesonide orodispersible tablet for maintaining remission of eosinophilic oesophagitis in people 18 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Budesonide oral suspension for inducing and maintaining remission of eosinophilic oesophagitis in people 2 to 17 years [ID6761]

    Awaiting development Reference number: GID-TA12464 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    Awaiting development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    Awaiting development

  7. Perfusion-induced systemic hyperthermia for the treatment of advanced lung cancer

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  8. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]

    Awaiting development Reference number: GID-TA11489 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]

    Awaiting development Reference number: GID-TA11469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810]

    Awaiting development Reference number: GID-TA11202 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development Reference number: GID-TA10723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Lomitapide for treating homozygous familial hypercholesterolaemia in people 5 to 17 years [TSID 12085]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Doravirine-islatravir for previously untreated HIV-1 infection [TSID12172]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment [TSID12171]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]

    Awaiting development Reference number: GID-TA10426 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development